Greenblatt D J
Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA 02111.
J Clin Psychiatry. 1992 Jun;53 Suppl:7-13.
The "revolution" in pharmacologic treatment of insomnia began in 1970 with the availability of flurazepam, the first of the benzodiazepine hypnotics. Flurazepam largely replaced all other hypnotics during the decade of the 1970s. The second revolution began in the early 1980s as shorter half-life hypnotics, triazolam and temazepam, became available and began to replace flurazepam. The decade of the 1990s will probably see a more balanced pattern of benzodiazepine hypnotic use, as well as use of newer nonbenzodiazepine hypnotics. Among available benzodiazepines, all have the capacity to produce dose- and concentration-dependent sedation, drowsiness, performance impairment, and amnesia. Benzodiazepine-induced amnestic effects are characterized by either impairment of information acquisition, impairment of consolidation and storage, or both. In general, apparent clinical differences among benzodiazepine hypnotics are explained by differences in pharmacokinetic properties of absorption, distribution, elimination, and clearance.
失眠药物治疗的“革命”始于1970年氟西泮的问世,它是第一代苯二氮䓬类催眠药。在20世纪70年代,氟西泮基本上取代了所有其他催眠药。第二次革命始于20世纪80年代初,随着半衰期较短的催眠药三唑仑和替马西泮的出现,它们开始取代氟西泮。20世纪90年代可能会出现苯二氮䓬类催眠药使用模式更加平衡的情况,同时也会使用更新的非苯二氮䓬类催眠药。在现有的苯二氮䓬类药物中,所有药物都有能力产生剂量和浓度依赖性的镇静、嗜睡、行为能力受损和失忆。苯二氮䓬类药物引起的失忆效应的特点是信息获取受损、巩固和存储受损,或两者皆有。一般来说,苯二氮䓬类催眠药之间明显的临床差异可以通过吸收、分布、消除和清除的药代动力学特性差异来解释。